Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Kite Pharma (KITE)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Kite Pharma's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Kite Pharma historical data, for real-time data please try another search
179.79 0.00    0.00%
02/10 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 179.55 - 179.95
Kite Pharma 179.79 0.00 0.00%

KITE Candlestick Patterns

 
Dozens of bullish and bearish live candlestick chart patterns for the Kite Pharma stock and use them to predict future market behavior. The Kite Pharma stock patterns are available in a variety of time frames for both long and short term investments. Gain a trading edge with the auto pattern recognition feature and gain an insight into what the patterns mean.
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Customize

Candlestick Patterns

Time Frame
Pattern Indication
Type
Reliability
Pattern Timeframe Reliability Candles Ago Candle Time
Emerging Patterns
Deliberation Bearish 1M Current
Hanging Man 15 Current
Completed Patterns
Deliberation Bearish 1M 6 Apr 17
Doji Star Bearish 1M 6 Apr 17
Evening Doji Star 1M 13 Sep 16
Doji Star Bearish 1M 14 Aug 16
Engulfing Bearish 1M 22 Dec 15
Upside Gap Three Methods 1M 22 Dec 15
Engulfing Bearish 1W 28 Mar 19, 2017
Engulfing Bearish 1W 32 Feb 19, 2017
Three Inside Up 1W 35 Jan 29, 2017
Falling Three Methods 1W 37 Jan 15, 2017
Bullish Engulfing 1M 38 Aug 14
Shooting Star 5H 38 Sep 07, 2017 07:00AM
Engulfing Bearish 1W 43 Dec 04, 2016
Engulfing Bearish 1W 45 Nov 20, 2016
Doji Star Bearish 1W 46 Nov 13, 2016
Harami Cross 1D 47 Jul 26, 2017
Dark Cloud Cover 1D 48 Jul 25, 2017
Harami Cross Bearish 1W 52 Oct 02, 2016
Three Outside Up 1D 52 Jul 19, 2017
Bullish Engulfing 1D 53 Jul 18, 2017
Thrusting Bearish 1W 55 Sep 11, 2016
Harami Bullish 1W 57 Aug 28, 2016
Harami Cross 1W 57 Aug 28, 2016
Evening Doji Star 1W 58 Aug 21, 2016
Harami Bullish 5H 58 Aug 24, 2017 08:00AM
Harami Cross 5H 58 Aug 24, 2017 08:00AM
Doji Star Bearish 1W 59 Aug 14, 2016
Shooting Star 1D 64 Jun 30, 2017
Doji Star Bearish 1D 65 Jun 29, 2017
Three Outside Up 5H 66 Aug 18, 2017 12:00PM
Bullish Engulfing 5H 67 Aug 18, 2017 07:00AM
Engulfing Bearish 5H 68 Aug 17, 2017 11:00AM
Advance Block Bearish 5H 69 Aug 17, 2017 06:00AM
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

KITE Comments

Write your thoughts about Kite Pharma
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Episcopolian OptionTrader
Episcopolian1 Apr 04, 2017 11:49AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Reason for the sell-off: People are gravitating to an old bad news, rather than good news. . Kite Pharma's lead product candidate shows high response rate in treatment-resistant NHL, two treatment-related death reported; shares off 4%. . Dec. 6, 2016 11:41 AM ET|About: Kite Pharma (KITE)|By: Douglas W. House, SA News Editor . Results from a pivotal Phase 1/2 clinical trial, ZUMA-1, assessing Kite Pharma's (KITE -3.7%) lead product candidate axicabtagene ciloleucel (KTE-C19) in patients with chemorefractory aggressive non-Hodgkin lymphoma (NHL) showed over 3/4 of patients responded to treatment. The data were presented at the 58th American Society of Hematology (ASH) annual meeting in San Diego..
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email